Romiplostim is effective for eltrombopag-refractory aplastic anemia: results of a retrospective study
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Hematology"
DOI: 10.1007/s12185-020-02971-1
Abstract: Eltrombopag (EPAG) and romiplostim (ROM), thrombopoietin receptor-agonists with demonstrated efficacy against aplastic anemia (AA) in prospective controlled studies, were authorized in Japan for use in adults with aplastic anemia in 2017 and 2019, respectively. So… read more here.
Keywords: anemia; aplastic anemia; eltrombopag; ten patients ... See more keywords
Romiplostim as adjunctive treatment of refractory amegakaryocytic immune thrombocytopenia in a dog.
Sign Up to like & getrecommendations! Published in 2020 at "Topics in companion animal medicine"
DOI: 10.1016/j.tcam.2020.100488
Abstract: A nine-year-old, intact male, mixed-breed dog was admitted with a three-day history of severe thrombocytopenia and bleeding diathesis. Physical examination revealed mucosal and cutaneous petechiae and ecchymoses, melena and gross hematuria. Clinicopathologic evaluation indicated severe… read more here.
Keywords: thrombocytopenia; treatment; adjunctive treatment; amegakaryocytic immune ... See more keywords
Efficacy and quality of life of Romiplostim in adults and children with immune thrombocytopenia: A review
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000032345
Abstract: Background: To systematically evaluate the clinical efficacy, drug safety and health-related quality of life (HRQoL) of Romiplostim in adult and child immune thrombocytopenia (ITP) patients. Methods: PubMed, EMBASE and Cohrane library databases were searched for… read more here.
Keywords: immune thrombocytopenia; romiplostim; adults children; efficacy ... See more keywords
Efficacy and safety of romiplostim in refractory aplastic anaemia: a Phase II/III, multicentre, open‐label study
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Haematology"
DOI: 10.1111/bjh.17190
Abstract: A previous dose‐finding study has suggested that romiplostim is effective in patients with refractory aplastic anaemia (AA) and 10 µg/kg once weekly was recommended as a starting dose. In this Phase II/III, multicentre, open‐label study,… read more here.
Keywords: refractory aplastic; study; aplastic anaemia; phase iii ... See more keywords
Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18081
Abstract: Patients with immune thrombocytopenia (ITP) may respond to one thrombopoietin receptor agonist (TPO‐RA) but not another. Limited data are available describing outcomes in patients who switched from romiplostim or eltrombopag to avatrombopag, a newer oral… read more here.
Keywords: eltrombopag romiplostim; immune thrombocytopenia; romiplostim; romiplostim eltrombopag ... See more keywords
Generic romiplostim for children with persistent or chronic immune thrombocytopenia: Experience from a tertiary care centre in North India
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18126
Abstract: Thrombopoietin receptor agonists are important therapeutic option in children with immune thrombocytopenia (ITP). We evaluated the response, efficacy, safety of a generic form of romiplostim manufactured in India for treating children with persistent/chronic ITP at… read more here.
Keywords: immune thrombocytopenia; romiplostim; children persistent; persistent chronic ... See more keywords
Predictors of Remission in Adults with Immune Thrombocytopenia Treated with Romiplostim
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-109791
Abstract: Background: In adults with ITP, thrombopoietin receptor agonists (TPO-RA) are often assumed to be lifelong therapy. However, some patients achieve treatment-free remission (TFR) by maintaining hemostatic platelet counts after discontinuing TPO-RA, despite not replacing them… read more here.
Keywords: research; board; research funding; consultancy ... See more keywords
Romiplostim Treatment Pattern of Adult Chronic Immune Thrombocytopenia in Routine Clinical Care in Three Nordic Countries
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-110965
Abstract: Introduction Romiplostim was approved in 2009 in Europe for treatment of adult chronic immune thrombocytopenia (cITP) in splenectomized patients, refractory to other ITP treatments, and as second-line treatment for adult non-splenectomized patients. In 2016 the… read more here.
Keywords: platelet count; line; treatment; line treatment ... See more keywords
Efficacy and Safety of Biosimilar Romiplostim in Immune Thrombocytopenic Purpura : Single Centre Retrospective Data Analysis
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-138392
Abstract: Introduction: Thrombopoietin receptor agonist (TPO RA) is an approved second line of treatment in Persistent and Chronic Immune Thrombocytopenic Purpura (ITP).However in India due to cost constraints, the majority prefer Immunosuppression therapy. A biosimilar of… read more here.
Keywords: response; cumm; itp; biosimilar romiplostim ... See more keywords
A single-arm, long-term efficacy and safety study of subcutaneous romiplostim in children with immune thrombocytopenia
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021006014
Abstract: Key Points • Long-term romiplostim treatment is effective in children with primary ITP; serial bone marrow biopsy results showed no new safety concerns.• Romiplostim injections resulted in 8 AEs of neutralizing antibodies (romiplostim, n =… read more here.
Keywords: long term; safety; romiplostim; arm long ... See more keywords
Scaling Pharmacodynamics from Rats to Humans to Support Erythropoietin and Romiplostim Combination Therapy to Treat Erythropoietin-Resistant Anemia
Sign Up to like & getrecommendations! Published in 2023 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics15020344
Abstract: Recombinant human erythropoietin (rHuEPO) is one of the most effective drugs for the treatment of anemia in patients with chronic kidney disease. However, EPO-resistance is an important contributor to the increased risk of adverse effects.… read more here.
Keywords: combination therapy; romiplostim; combination; erythropoietin ... See more keywords